| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK, Aug. 20 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation (Nasdaq: GNBT). The full 64-page report can be found at http://www.crystalra.com.
Generex Biotechnology Corporation ("Generex" or "the Company") is a specialty pharmaceutical company that aims to research, develop, and commercialize drug delivery systems and technologies to treat autoimmune disorders, cancers, and infectious and metabolic diseases. Generex's RapidMist(TM) platform technology is a device and liquid formulation combination that can deliver medications to the bloodstream via the buccal mucosa at an improved absorption rate. This formulation is partially composed of absorption enhancers, called surfactants, which enable the oral delivery of a range of compounds, including macromolecules. While the device's appearance is similar to a pulmonary inhaler, the technology differs greatly. Traditional inhalers deliver medication into the lungs; RapidMist(TM) delivers larger-sized molecules into the buccal mucosa of the mouth, with no lung deposition.
The Company's lead product, Generex Oral-lyn(TM), is a buccal insulin
spray that uses the RapidMist(TM) platform to treat Type 1 and Type 2
diabetes, which has demonstrated safety and efficacy in clinical trials.
Generex Oral-lyn(TM) is currently approved in Ecuador and India. Generex
has enrolled over 150 patients in a Phase III trial of Generex Oral-lyn(TM)
at 39 clinical sites worldwide. The Company is also developing
MetControl(TM) gum to avoid some of the adverse side effects associated
with generic metformin tablets. This product c
'/>"/>
| SOURCE Crystal Research Associates, LLC Copyright©2008 PR Newswire. All rights reserved |